N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for oncology, gene therapy and vaccines using its unique silica nanoparticle delivery system called Nuvec®. N4 Pharma’s business model is to partner with companies developing novel antigens in these fields to use Nuvec® as the delivery vehicle for these antigens. As these products progress through pre‐clinical and clinical programs, N4 Pharma will seek to receive upfront payments, milestone payments and ultimately royalty payments once products reach the market. For further information on the Company visit www.n4pharma.com or sign up at investors.n4pharma.com.
Authors
Nigel Theobald
Nigel Theobald, Chief Executive Officer at N4 Pharma, has over 25 years’ experience in healthcare and in building businesses, strategy development and its implementation and a strong network cov...
